BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives $389.73 Average Target Price from Analysts

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has received a consensus recommendation of “Moderate Buy” from the fourteen research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, ten have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $391.00.

A number of research firms have recently issued reports on ONC. Guggenheim increased their price objective on shares of BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research report on Thursday. Wells Fargo & Company began coverage on shares of BeOne Medicines in a research report on Monday, May 4th. They set an “overweight” rating and a $400.00 price objective on the stock. Sanford C. Bernstein raised shares of BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price objective on the stock in a research report on Monday, January 12th. Jefferies Financial Group cut shares of BeOne Medicines from a “buy” rating to a “hold” rating and cut their price objective for the stock from $420.00 to $290.00 in a research report on Monday, March 16th. Finally, Wolfe Research initiated coverage on shares of BeOne Medicines in a research report on Friday, March 27th. They set an “outperform” rating and a $340.00 price objective on the stock.

Insiders Place Their Bets

In related news, SVP Chan Henry Lee sold 341 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $300.00, for a total value of $102,300.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 6.19% of the company’s stock.

Hedge Funds Weigh In On BeOne Medicines

Several large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP lifted its position in BeOne Medicines by 15.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 56,879 shares of the company’s stock valued at $16,859,000 after acquiring an additional 7,815 shares in the last quarter. Parallel Advisors LLC lifted its position in BeOne Medicines by 24.0% in the 1st quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock valued at $104,000 after acquiring an additional 68 shares in the last quarter. KBC Group NV lifted its position in BeOne Medicines by 5.6% in the 1st quarter. KBC Group NV now owns 9,488 shares of the company’s stock valued at $2,818,000 after acquiring an additional 502 shares in the last quarter. SEB Asset Management AB bought a new position in BeOne Medicines in the 1st quarter valued at about $16,653,000. Finally, AIA Group Ltd lifted its position in BeOne Medicines by 15.1% in the 1st quarter. AIA Group Ltd now owns 26,077 shares of the company’s stock valued at $7,744,000 after acquiring an additional 3,430 shares in the last quarter. Institutional investors own 48.55% of the company’s stock.

BeOne Medicines Price Performance

ONC stock opened at $312.12 on Monday. The stock has a market capitalization of $34.25 billion, a PE ratio of 69.83 and a beta of 0.50. The company’s 50-day moving average is $301.40 and its 200-day moving average is $322.00. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. BeOne Medicines has a 1 year low of $218.31 and a 1 year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The company had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. Equities research analysts expect that BeOne Medicines will post 5.3 EPS for the current fiscal year.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.